| HUMAN-TRIAL | evidence | Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) | Semaglutide | Liver health · human-rct · n = 1205 | — |
| HUMAN-TRIAL | evidence | A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Japanese Men | Semaglutide | Glycemic control · human-rct · n = 24 | — |
| HUMAN-TRIAL | evidence | Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder | Semaglutide | human-rct · n = 100 | — |
| HUMAN-TRIAL | evidence | A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice (SURE GERMANY) | Semaglutide | Glycemic control · human-observational · n = 789 | — |
| HUMAN-TRIAL | evidence | GLP-1R Agonist Treatment for Opioid Use Disorder | Ozempic | Addiction & substance use · human-rct · n = 200 | — |
| HUMAN-TRIAL | evidence | Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide. | Semaglutide | Kidney function · human-rct · n = 90 | — |
| HUMAN-TRIAL | evidence | The Effects of Semaglutide on Taste, Tongue Tissue Transcriptome, Gastric Emptying and Central Neural Response in Women With PCOS and Obesity | Ozempic | human-rct · n = 30 | — |
| HUMAN-TRIAL | evidence | Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes | Ozempic | Glycemic control · n = 300 | — |
| HUMAN-TRIAL | evidence | Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity? | Wegovy | Addiction & substance use · human-rct · n = 108 | — |
| HUMAN-TRIAL | evidence | Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity | Semaglutide | Weight & fat loss · human-rct · n = 66 | — |
| HUMAN-TRIAL | evidence | Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial | Ozempic | human-rct · n = 60 | — |
| HUMAN-TRIAL | evidence | Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV | Ozempic | human-rct · n = 40 | — |
| HUMAN-TRIAL | evidence | Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus. | Semaglutide | Glycemic control · human-rct · n = 504 | — |
| HUMAN-TRIAL | evidence | The Safety, Tolerability, and Pharmacokinetics of of SYH9017 in Chinese Participants With Overweight and Obesity | Wegovy | Weight & fat loss · human-rct · n = 66 | — |
| HUMAN-TRIAL | evidence | Effect of Renal Impairment on the Pharmacokinetics of NN9535 | NN9535 | Glycemic control · human-observational · n = 62 | — |
| HUMAN-TRIAL | evidence | GLP1R in Parkinson's Disease | Semaglutide | human-rct · n = 120 | — |
| HUMAN-TRIAL | evidence | A Research Study to Compare Two Different Forms of Once-weekly Semaglutide in Two Different Injection Pens | Semaglutide | Weight & fat loss · human-rct · n = 111 | — |
| HUMAN-TRIAL | evidence | Semaglutide vs Sitagliptin | Semaglutide | Glycemic control · human-rct · n = 58 | — |
| HUMAN-TRIAL | evidence | Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients | Wegovy | Weight & fat loss · human-rct · n = 460 | — |
| HUMAN-TRIAL | evidence | Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth | Wegovy | Weight & fat loss · human-rct · n = 150 | — |
| HUMAN-TRIAL | evidence | Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy | Wegovy | human-rct · n = 30 | — |
| HUMAN-TRIAL | evidence | Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea | Rybelsus | Glycemic control · human-observational · n = 600 | — |
| HUMAN-TRIAL | evidence | Semaglutide 2.4mg for Low Responders After Bariatric Surgery | Wegovy | Weight & fat loss · human-rct · n = 152 | — |
| HUMAN-TRIAL | evidence | Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study | Semaglutide | human-rct · n = 1 | — |
| HUMAN-TRIAL | evidence | GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer | Semaglutide | human-observational · n = 30 | — |
| HUMAN-TRIAL | evidence | Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus | Semaglutide | human-observational · n = 50 | — |
| HUMAN-TRIAL | evidence | Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes | Semaglutide | Glycemic control · human-rct · n = 706 | — |
| HUMAN-TRIAL | evidence | Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment | Semaglutide | Neuroprotection · human-rct · n = 390 | — |
| HUMAN-TRIAL | evidence | Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology | Ozempic | Glycemic control · human-rct · n = 200 | — |
| HUMAN-TRIAL | evidence | Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial | Semaglutide | human-rct · n = 436 | — |
| HUMAN-TRIAL | evidence | A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III | Semaglutide | human-rct · n = 121 | — |
| HUMAN-TRIAL | evidence | A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice | Semaglutide | Glycemic control · human-observational · n = 458 | — |
| HUMAN-TRIAL | evidence | Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects | Wegovy | Weight & fat loss · human-rct · n = 420 | — |
| HUMAN-TRIAL | evidence | Effect of Oral Semaglutide on Epicardial and Pericoronary Adipose Tissues in Type 2 Diabetes After Myocardial Infarction | Rybelsus | human-rct · n = 88 | — |
| HUMAN-TRIAL | evidence | A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight | Semaglutide | Weight & fat loss · human-rct · n = 331 | — |
| HUMAN-TRIAL | evidence | Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data | Semaglutide | Glycemic control · human-observational · n = 58387 | — |
| HUMAN-TRIAL | evidence | Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation | Semaglutide | human-rct · n = 240 | — |
| HUMAN-TRIAL | evidence | A Study to Evaluate Safety, Tolerability and pK of Semaglutide ER Injectable Suspension in Healthy, Adult Human Subjects | Semaglutide | Glycemic control · human-observational · n = 14 | — |
| HUMAN-TRIAL | evidence | Improved Treatment and Monitoring of Alzheimer's Disease | Rybelsus | Cognition & memory · human-rct · n = 180 | — |
| HUMAN-TRIAL | evidence | Semaglutide in Auto-HSCT | Ozempic | human-rct · n = 40 | — |
| HUMAN-TRIAL | evidence | A Research Study Comparing the Effect of Different Dosing Conditions on Blood Levels of Semaglutide in a New Tablet Composition in Healthy Participants | Semaglutide | human-rct · n = 121 | — |
| HUMAN-TRIAL | evidence | A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range | Ozempic | Weight & fat loss · human-observational · n = 32 | — |
| HUMAN-TRIAL | evidence | A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet | Semaglutide | human-rct · n = 152 | — |
| HUMAN-TRIAL | evidence | Semaglutide in Patients Undergoing Transcatether Aortic Valve Replacement | Wegovy | Lipid & cardiovascular markers · human-rct · n = 826 | — |
| HUMAN-TRIAL | evidence | Efficacy and Safety of QLG1091 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes | Rybelsus | Glycemic control · human-rct · n = 478 | — |
| REGULATORY | regulatory | D-0471-2026 — Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, OR | FDA | — | 2026-03-06 |
| REGULATORY | regulatory | D-0393-2026 — Semaglutide Inj., 2 mg x 5, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, NDC 84223-001-06 | FDA | — | 2026-02-26 |
| REGULATORY | regulatory | D-0392-2026 — Semaglutide Inj, 2mg x 10, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, NDC 84223-001-07. | FDA | — | 2026-02-26 |
| REGULATORY | regulatory | D-0380-2026 — Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50g, NDC 84385-106-04; e) 100g, NDC 84385-106-05Manufacturer: Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing S… | FDA | — | 2026-02-13 |
| REGULATORY | regulatory | D-0379-2026 — Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50g, NDC 84385-106-04 Manufacturer: Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street, Limin Development Zo… | FDA | — | 2026-02-13 |